Redeye comments on Faron’s updated data from the Phase I/II BEXMAB trial in frontline high-risk MDS,...
Redeye updates on W5 Solutions after Q2-results which saw weaker-than-expected profitability while a...
Redeye updates its estimates following Freemelt’s Q2 report, which was a record quarter, both in ter...
We expect a solid Q2 and raise '25e-'26e EBIT by 1% '25e-'28e EBIT CAGR of 31% driven by senior subs...
Føroya Banki reported Q2 2025 net profit of DKK 93m, DKK 15m (19%) above our estimate.
Q2 EBITA EUR 2.5m (ABGSCe EUR 6.9m) We cut '25e-'27e adj.
Report out 22 August '25e-'26e sales cut by 19-15% on lower expected machine deliveries 3y deal sign...
Redeye comments on W5 Solutions Q2-results where revenue was in line with expectations while profita...
Q2 sales on par with FY'24, below ABGSCe only on delivery timings Deliveries likely pushed into H2, ...
North American weakness behind yesterday's Q2 PW FY guidance cut more than feared Estimates likely d...
Ahead of CapMan's Q2 2025, we make slight revisions to our estimates, mainly reflecting the CAERUS D...
We lower adjusted EBIT by 13% for 2025E and 6% for 2026E-27E.
Redeye views BeammWave’s rights issue of up to SEK65m as a positive and necessary step to expedite i...
Redeye leaves its preview of RaySearch’s Q2 2025 results due on Friday, August 8.
Redeye comments on last week's news where Google lost its antitrust appeal related to its app store ...
